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Abstract The value of combination therapy with inhaled
corticosteroids and long-acting b-agonists (ICS/LABA) is
well recognized in the management of asthma and chronic
obstructive pulmonary disease (COPD). Despite differ-
ences in the pharmacological properties between two well-
established ICS/LABA products (budesonide/formoterol
and fluticasone/salmeterol), data from randomized clinical
trials (RCTs) and meta-analyses suggest that these two
products perform similarly under RCT conditions. In con-
trast, a few recently reported real-world comparative
effectiveness studies have suggested that there are sub-
stantial differences between ICS/LABA combination
treatments in terms of clinical and healthcare outcomes in
patients with asthma or COPD. The purpose of this article
is to provide a brief review of the benefits, as well as the
limitations, of comparative effectiveness research (CER) in
the therapeutic area of asthma and COPD. We conducted a
structured literature review of the current CER studies on
ICS/LABA combinations in asthma and COPD. These
articles were then used to illustrate the unique challenges of
CER studies, providing a summary of study results and
limitations. We focus particularly on difficult biases and
confounding factors that may be introduced before, during,
and after the initiation of therapy. Beyond being a review
of these two ICS/LABA combination treatments, this
article is intended to help those who wish to assess the
quality of CER published projects in asthma and COPD, or
guide investigators who wish to design new CER studies
for chronic respiratory disease treatments.
Key Points
A number of new treatments for asthma and chronic
obstructive pulmonary disease (COPD) were
recently released, with several more on the horizon.
This has sparked interest in the comparative
effectiveness among the available inhaled therapies.
The natural histories of asthma and COPD
presentation and progression present many unique
challenges for comparative effectiveness research.
Comorbidities, disease heterogeneity, and poor
treatment adherence are just a few of the problems
that can introduce bias into the analysis if not
effectively addressed in the study design.
1 Introduction
The goal of comparative effectiveness research (CER) is to
measure the real-life benefits and risks of treatments. The
Institute of Medicine defines CER as ‘‘the generation and
synthesis of evidence that compares the benefits and harms
of alternative methods to prevent, diagnose, treat, and
monitor a clinical condition or to improve delivery of care.
The purpose of CER is to assist consumers, clinicians,
purchasers, and policymakers to make informed decisions
that will improve healthcare at both the individual and
population levels’’ [1]. Proof of whether or not a treatment
can work is known as efficacy, while the benefit of that
treatment in routine clinical practice is known as effec-
tiveness. Efficacy is usually established by randomized
clinical trials (RCTs), which are considered to be the ‘gold
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standard’ for proof of treatment benefit, but RCTs do have
important limitations, including highly selected study
populations and artificial clinical conditions. Effectiveness
studies are needed to demonstrate that treatments still have
the intended benefits when they are used in broader unse-
lected patient populations and routine clinical practice.
CER attempts to capture the differences in clinical benefits
among similar treatments when used in the general
population.
The availability of well-established inhaled combination
corticosteroid and long-acting b-agonist (ICS/LABA)
products [budesonide/formoterol (BFC) and fluticasone/
salmeterol (FSC)] in the management of asthma and
chronic obstructive pulmonary disease (COPD) creates an
opportunity to examine the benefits, as well as limitations,
of CER in the therapeutic area of chronic respiratory dis-
ease. Both of these combination inhalers have proven
efficacy in both asthma and COPD (a third combination,
mometasone/formoterol, is approved only for asthma), and
data from RCTs and meta-analyses suggest that these
products perform similarly under controlled RCT condi-
tions [2–7]. The role of ICS/LABA combination therapy
for patients with persistent asthma is well established,
while the role of combination therapy in COPD is not as
clear (Fig. 1). The only head-to-head comparisons of ICS/
LABA combinations in asthma found that any differences
in efficacy between them were slight, and in their primary
endpoints, not statistically significant [6]. In contrast, some
recently reported real-world, comparative effectiveness
studies have suggested that there are differences between
ICS/LABA combination treatments in a variety of clinical
outcomes. These discrepancies are intriguing, but there are
several unique features of asthma and COPD disease
pathophysiology, progression, and management that need
to be considered when interpreting CER studies, as well as
very important limitations in study design. In this review,
we examine the clinical trajectory of ICS/LABA use in
asthma and COPD and how study design problems during
different time periods may result in significant biases in
CER research. We present a current review of published
CER studies that have directly compared BFC with FSC,
and examine how they may or may not have dealt with
these study design issues. Finally, we summarize the
practical, clinical implications of these CER studies as well
as the knowledge gaps that remain, and look at what les-
sons can be learned for the development of new therapeutic
options.
2 Literature Review
We conducted a literature review using both PubMed and
Thomson Reuters Web of Science databases for studies
comparing ICS/LABA treatments, spanning the time period
1 January 1997 through 2 October 2013. Multiple searches
were conducted. Search terms included fluticasone, salme-
terol, budesonide, and formoterol. Initially the search was
broad and also included terms for mometasone furoate and
beclomethasone formoterol. A total of 330 unique citations
were identified from the broad search process. The abstracts
for these were reviewed, and based on that information the
following were excluded from further review: 124 review
articles, 118 clinical trial studies, 35 non-relevant studies
(e.g. generic studies, inhaler mechanism effectiveness, only
ICS treatment, or simulation study), and 14 non-study
documents (book chapters, viewpoints, or editorials). We
then reviewed the remaining 39 articles in detail. Of these,
25 articles did not present comparative effectiveness find-
ings for the BFC and FSC or were duplicative of ones that
did, and 14 articles described observational comparative
effectiveness studies of BFC and FSC; 9 for asthma and 5
for COPD. Highlights of these studies are summarized in
Tables 1, 2, 3 and 4 [9–22].
3 The Trajectory of Asthma and Chronic Obstructive
Pulmonary Disease (COPD) Treatment
A major difference between RCTs and CER is that the
index date, or ‘day one’ of treatment, in an RCT for an
asthma or COPD medication typically starts when the
patient is at a stable baseline, at least several weeks after
their last exacerbation. In real-life, asthma or COPD
patients usually start taking medications when they are
sick. In studies that have examined the natural history of
COPD in the time before and after the first diagnosis of
COPD, the diagnosis typically occurs during an exacerba-
tion, respiratory infection, or non-respiratory acute medical
event, and respiratory medications are often dispensed
along with antibiotics and other drugs during that time [23,
24]. Asthma diagnoses are also more likely to be made at
times when patients are symptomatic [25, 26]. Therefore,
ICS/LABA treatment in the real-world is usually pre-
scribed when asthma and COPD patients are unstable and
often have other complicating problems such as infections
or cardiovascular complications. When contemplating a
CER study in asthma and COPD, it is useful to partition the
time periods into the time of the initial treatment with a
new medication (the index date), the time before the new
medication was dispensed (the baseline period), and the
time after the medication was dispensed (the follow-up
period). Each of these periods is associated with unique
factors that result in selection biases, measurement errors,
or potential confounding that are likely to affect clinical
outcomes. In the following sections, we will examine these
features by each time period in detail, and examine how
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these potential problems have been handled in the CER
studies for ICS/LABA treatment to date.
4 The Index Date
In CER of ICS/LABA combinations, the index date is
commonly the date of the first prescription fill for the new
treatment after the asthma or COPD diagnosis is estab-
lished. In Table 1, the majority are longitudinal cohort
analyses with index dates that are based on this definition.
The index date is a logical choice as the start of the analysis
period because it is safe to assume that the patient first
started using the ICS/LABA inhaler on or near that date,
and whatever benefits and side effects attributable to the
treatment will begin to accrue at that time. However, that
a
b
Fig. 1 Role of ICS/LABA combination therapy in (a) asthma and
(b) COPD [8]. Asthma guidelines reproduced with permission from
the National Asthma Education and Prevention Program [8]. Refer to
the original document for full guideline notes (http://www.nhlbi.nih.
gov/guidelines/asthma/09_sec4_lt_12.pdf, accessed 17 March 2014).
ACP American College of Physicians, ACCP American College of
Chest Physicians, ATS American Thoracic Society, COPD chronic
obstructive pulmonary disease, EIB exercise-induced bronchospasm,
ERS European Respiratory Society, FEV1 forced expiratory volume in
1 second, ICS inhaled corticosteroid, LABA long-acting inhaled b2-
agonist, LTRA leukotriene receptor antagonist, SABA short-acting
inhaled b2-agonist





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































748 D. W. Mapel, M. H. Roberts
assumption may not be true in clinics where free drug
samples are dispensed, wherein there may be a gap of
weeks to months between the office visit when treatment
was started and the first ICS/LABA prescription drug fill,
resulting in a bias in follow-up time. Therefore, one needs
to be familiar with the policies about sampling in the health
systems one is studying and the likelihood that patients are
dispensed medications that do not appear in the database.
Unfortunately, studies rarely describe what was hap-
pening to the patient on the index date that caused them to
be treated. These circumstances are important because they
are likely to affect the patient’s outcome during follow-up.
For example, if the patient was experiencing an asthma or
COPD exacerbation at the time it was prescribed, their risk
for another exacerbation during the next few months will
be substantially higher than for someone who had not had a
recent exacerbation [27, 28]. If the ICS/LABA prescription
was provided during an emergency department visit, it is
likely that the patient will have different adherence with
long-term treatment than someone who is prescribed one
during a scheduled office visit [29]. If the prescription is
written by a pulmonologist, then it is more likely that there
will have been a pulmonary function test or other testing
confirming the diagnosis than if written by a primary care
provider. If the index date is at or near the time of a hos-
pitalization, then associated comorbidities such as heart
disease or pneumonia may be more likely to affect sub-
sequent outcomes [30].
One way to deal with the problem of heterogeneous clinical
presentations is to match patients based on the clinical setting
where they started ICS/LABA treatment, such as a clinic visit,
ED visit, or hospitalization. Another way is to match patients
based on the specialty of the prescribing physician, such as
pulmonary or allergy specialists versus primary care provider.
In studies where COPD or asthma exacerbations are an out-
come of interest, it is very important to match on exacerba-
tions that occurred on or near the index date because one of the
best predictors of future exacerbations is the history of prior
exacerbations [27, 31, 32].
One also needs to be aware that physicians may not be
free to choose which ICS/LABA product the patient will
get; the choice is often made by pharmacy benefit man-
agers who negotiate a lower price for one ICS/LABA
product or the other, which then becomes the more readily
available product on the formulary [33]. In that circum-
stance, the fact that a patient is not using the less expensive
product is an indication that there is something unusual
about the patient that may affect their outcomes. When
comparing COPD or asthma patients among several health
systems, one must be aware of those with a formulary that
heavily favors one product because differences among
heavily biased cohorts may be more likely to reflect group
clinical characteristics than treatment effects.
4.1 Index Dates in Cross-Sectional Studies
A few of the CER studies in asthma were based in respi-
ratory clinics and are purely cross-sectional, meaning that
all patients at the initiation of the research have already
been taking their medications for weeks to years before the
first day of the study (Table 1). The index date for these
cross-sectional studies is usually the date of enrollment,
and because of the variable length of medication use at the
start, lead time bias is inevitable. Clinic-based studies are
necessary when the endpoints of interest are asthma
symptom control and health-related well-being, which are
measured using standardized questionnaires. These pro-
jects also tended to be more similar to RCTs in that they
excluded persons who had a recent exacerbation, they
excluded those with COPD or other serious chronic dis-
eases, and they included a relatively homogeneous selected
population of persons who most likely had severe asthma at
one time and were thus referred to a specialist’s office.
While reducing confounding influences, these criteria also
limit the generalizability of the results. Unlike RCTs, these
projects are obviously not blinded or randomized, making
them highly susceptible to the biases that affect any
observational study.
4.2 Misclassification Errors in Asthma and COPD
Comparative Effectiveness Research (CER)
Misclassification errors (misdiagnoses) are common among
persons labeled with either asthma or COPD. One primary
care-based clinical study found that almost half of their
patients with a physician diagnosis of COPD did not have
airflow obstruction when tested by spirometry [34]. In
addition, in a study of 496 randomly selected patients
diagnosed with asthma from eight cities in Canada, 150
(30 %) did not have asthma after a complete evaluation
including methacholine challenge testing. [35] For asthma,
there can also be difficulties in accurately distinguishing
between levels of disease severity [36–38]. To decrease the
risk of disease misclassification, some database studies
require multiple outpatient COPD or asthma diagnoses
over a specified time period, or at least one diagnosis
during a hospitalization. Hospitalization diagnoses are
assumed to be more valid because patients are more likely
to have had a more thorough assessment than during an
office visit, although that is not always a safe assumption.
[39]
4.3 Inclusion and Exclusion Criteria
In asthma or COPD CER studies there is a tendency to use
the same inclusion and exclusion criteria used in asthma or
COPD RCTs. It is often driven by a desire to demonstrate
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effectiveness in CER that is similar to efficacy in RCT.
However, when doctors in the real-world prescribe asthma
or COPD medications, they are not limited to the strict
inclusion and exclusion criteria that are used for RCTs.
Like it or not, physicians will immediately begin testing the
boundaries unexplored by RCTs as soon as a drug is on the
market. Relative effectiveness of treatment in the general
population should reflect treatment in the general popula-
tion. If there is a desire to replicate RCT results, then
secondary analyses that systematically examine the impact
of various inclusion and exclusion criteria can serve that
purpose and additionally may yield unique and useful
information.
Exclusion criteria deserve special consideration in CER
studies because that is where the unintended effects of new
treatments are likely to be found. Drug studies attempting
to prove efficacy in RCTs typically exclude unstable
patients, those with severe comorbidities, or persons who
are not likely to be compliant with therapy, because these
patients increase safety monitoring concerns while also
reducing the power to observe clinical benefits. However,
excluding these patients also reduces the power of RCTs to
capture negative side effects, particularly those that are
more likely in the excluded populations. One of the unique
advantages of CER is that the risk or benefits of treatment
for these excluded, unstudied patients can now be captured
and described.
It is common for COPD patients to have other respira-
tory diagnoses, especially asthma. In a cohort of 42,565
COPD patients treated in managed care systems in the US,
27 % also had an asthma diagnosis within the last year
[40]. The impact on measured outcomes of having a
combined asthma and COPD diagnosis is variable
depending on the outcome, but most studies have found
increased risk for exacerbations [41]. Furthermore, most
observational database studies do find that a combined
diagnosis of COPD and asthma does affect treatment,
particularly the selection of ICS/LABA combinations ver-
sus inhaled anti-muscarinic treatments [42]. Unfortunately,
most CER studies in COPD to date have simply excluded
patients with any diagnosis of asthma. Lung cancer is
common in older COPD cohorts (4–7 % in cross-sectional
cohorts) [40], and because of its very high case fatality rate,
it has a significant impact in longitudinal studies [43].
Depending on the objectives of the study, investigators
may need to make a systematic effort to capture specific
respiratory comorbidities.
Another common way to reduce selection bias and
create balanced ICS/LABA cohorts similar to RCT popu-
lations is to use case-control methods. It is possible to
match on just a few major demographic and clinical factors
[17], but most studies have used propensity score matching
(PSM) techniques which allow more comprehensive
matching using a broader array of clinical variables
(Table 1). The obvious benefit of matching is that known
confounding factors are more likely to be balanced among
the comparison groups, but PSM still has a number of very
important limitations [44]. First, matching limits the study
cohorts to the size of the smaller treatment population. If
one of the treatment groups is substantially smaller than the
other, then most of the persons in the larger group are
dropped from the analysis, which leads to sample selection
bias and may seriously compromise the generalizability of
the results. Second, PSM will help balance the selected
variables, but any unselected or unmeasured variables that
affect outcomes may continue to be unbalanced. This is
very important in observational studies where attitudes
about treatment and adherence with therapy are often not
measurable. Finally, when one matches on a clinical
parameter, then one’s ability to measure how that factor
affects the outcomes is compromised [45]. For example, if
men are more likely than women to benefit from the
reduction in COPD or asthma exacerbations attributable to
ICS-LABA treatment, then matching by sex will bias the
risk estimates for exacerbations among men towards the
null, and eliminate the possibility of examining interactive
effects between ICS-LABA treatment, sex, and exacerba-
tion risk.
5 The Baseline Period
Utilization data collected during the baseline period is
often used to establish the diagnosis of asthma or COPD,
capture items that are associated with disease severity, and
identify comorbid diseases and conditions (Table 2). The
duration of the baseline period is typically 12 months,
which helps to ensure that the treatment dispensed on the
index date is a new treatment. Importantly, a 12-month
baseline also allows for the seasonal variability in asthma
and COPD exacerbations. Within the baseline period, the
timing of events may be important, in particular those
occurring just prior to the index date. For example, an
emergency department visit with a discharge diagnosis of
bronchitis that occurred 1 week prior to hospitalization for
asthma is most likely a very different syndrome than that of
a patient who was seen in a pulmonologist’s office
6 months before the index date with a chronic cough.
The approach to dealing with confounders is one of the
most important differences between RCTs and CER. In
randomized trials, treatment groups have randomly and
equally distributed known (e.g. age, comorbidities, sex)
and unknown (e.g. preferences and attitudes toward treat-
ment) confounding influences, leaving treatment as the
major difference between groups that may impact out-
comes. The challenge of CER is to adequately adjust for
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the many confounding factors that exist in these retro-
spective treatment populations. In asthma and COPD,
comorbid illnesses such as cardiovascular disease or psy-
chiatric illness are examples of known and very complex
confounders. It is important to keep in mind that even if it
were possible to fairly balance every known confounding
factor retrospectively, unknown factors will remain
unbalanced and could become sources of residual
confounding.
To capture baseline comorbidities that are likely to
affect subsequent treatment choices or outcomes, it is best
to use one of the standardized classification systems that
have been adapted for use in electronic databases con-
taining International Classification of Diseases, Ninth
Revision (ICD-9) or ICD, Tenth Revision (ICD-10) codes
[46]. The Charlson Comorbidity Index, and database ver-
sions such as the Charlson–Deyo Index, are popular for
identifying and weighting prognostically significant
comorbidities, although the validity of the original
weighting scheme is limited due to the improvement in
some disease outcomes since the first version was pub-
lished over 20 years ago [47]. The Elixhauser system
captures a broader range of comorbidities, and software for
database versions are publically available on the US
Agency for Healthcare Research and Quality website [48].
However, there are comorbidities of special interest in
asthma and COPD, such as obstructive sleep apnea, cor
pulmonale, allergic rhinitis, vascular disease, gastro-
esophageal reflux, and cardiac arrhythmias, that are missed
by some of these standardized systems. Therefore, it is
usually necessary to supplement standardized comorbidity
classification tools with the other respiratory diseases and
conditions associated with COPD and asthma that are
likely to affect outcomes.
The baseline period may also be used to estimate the
severity of asthma or COPD. It is reasonable to expect that
patients with unstable asthma or COPD will have more
hospitalizations and unscheduled clinic visits. Emergency
department visits may also be indicators for severity;
however, many patients, even in managed care systems,
may use emergency departments as their primary care
clinic, and thus emergency department visits not leading to
hospitalization tend to be more like clinic visits than hos-
pital stays [27]. Patients with more severe disease may also
have more documentation of respiratory symptoms in the
form of diagnosis codes; for example, dyspnea (ICD-9
codes 786.05/786.09) or wheezing (ICD-9 codes 786.07)
[49]. Oxygen use, or codes for hypoxemia or respiratory
failure, are also evidence of severe lung disease.
Medication use during the baseline period is also a
useful indicator of respiratory disease severity. Increased
rescue medication use (either short-acting b-agonists and/
or ipratropium bromide) in the baseline period is associated
with increased COPD exacerbations before and after the
index date [20]. Increased use of rescue medication is also
a marker for poor asthma control [50]. Thorough descrip-
tion of baseline use of both the total number and types of
medications used (e.g. oral steroids, xanthenes, leukotriene
inhibitors) is useful for characterization of the study
populations.
6 The Follow-up Period
The follow-up period has unique challenges (Table 3). The
biggest challenge is dealing with the poor treatment
adherence among asthma and COPD patients. As previ-
ously noted, the index date is commonly associated with an
exacerbation of asthma or COPD. Fortunately, the natural
history of most COPD exacerbations is that the symptoms
will resolve and the patient will return to their usual health
status prior to the exacerbation [51]. But as asthma and
COPD symptoms decrease, the benefits of maintenance
medications such as ICS/LABAs become less obvious to
patients, and they quite often conclude that they do not
need them anymore. Experience varies, but approximately
25 % of persons initially dispensed an ICS/LABA will not
get it refilled, and by 6 months more than half will have
discontinued it [29]. Although adherence with combined
inhalers tends to be better than for use of the individual
component medications, studies of ICS/LABA combina-
tions show that continuity of treatment in either asthma or
COPD is very poor [52–54]. Even in RCTs such as the
TORCH study where patients were very closely monitored,
44 % of those on placebo and 34 % on full treatment
stopped the medication before the end of the study,
resulting in a bias that affected the results [55].
The conventional treatment comparison method for
RCTs is the intent-to-treat analysis, wherein patients are
kept in their original treatment groups even if they have
stopped taking the medicine. Many respiratory CER studies
also simply follow the intent-to-treat design, even though
the adherence with treatment is far worse than that of RCTs
and a large proportion of patients labeled as treated with
BFC or FSC were dispensed only one inhaler for the entire
follow-up period. This obviously creates misclassification
errors, and importantly makes it far more likely that any
observed differences between treatment groups are biased
by factors associated with selection of treatment than by
any effect of the treatment itself.
While patients who are non-compliant create mis-
classification errors and other biases, the patients who are
compliant with ICS/LABA treatment create another prob-
lem—bias by indication. Patients who have more severe
asthma and COPD are more likely to experience chronic
symptoms, have higher risk of recurrent exacerbations, and
Comparative Effectiveness Research in Asthma and COPD 751
thus use more respiratory medications. Without effectively
addressing the problem of bias by indication, ICS/LABA
combinations can appear to increase the risk of asthma and
COPD exacerbations in the general populations, when in
fact the treatment is simply acting as a marker for more
severe disease.
Although treatment adherence is a fundamental problem
for CER studies, most ICS/LABA studies to date have not
been very thorough in capturing or describing how medi-
cations were actually used, or adjusting for adherence in
the analysis (Table 3). There are notable exceptions; for
example, the project by Suissa et al. [13] specifically
addressed the adherence problem by using both intent-to-
treat analyses and analyses while on-treatment only.
Adjusting for treatment compliance during follow-up is a
very difficult problem that is the subject of ongoing
research. Because of the problem of bias by indication,
simply making treatment a time-dependent variable is more
likely to introduce bias than adjust for it [56]. Micro-sim-
ulation models and marginal structural models are new
techniques that address the complex competing problems
of disease severity and treatment adherence, but have only
recently been applied to COPD [57].
Exacerbations are a popular endpoint for CER because
they have significant impact on other disease outcomes
such as quality of life, healthcare costs, hospitalizations,
disability, and mortality [58]. However, defining exacer-
bations is controversial, especially in retrospective studies.
The most common definitions for exacerbations of CER are
based on utilization, which is a very practical approach for
studies where utilization and cost are major endpoints [59].
Outpatient exacerbations are usually defined as outpatient
visits associated with prescription fills for oral corticoste-
roids (OCSs) and/or antibiotics, standard treatments for
acute asthma and COPD exacerbations. Occasional use of
oral steroids can be a reasonable indicator of an acute
exacerbation, but use of only antibiotics is less clear,
especially now that chronic use of azithromycin to prevent
COPD exacerbations is growing in popularity. If exacer-
bations are the primary endpoint in CER, chart abstraction
may be needed to validate the sensitivity and specificity of
exacerbation definitions.
When utilization is used to define exacerbations, one
also has to decide how closely the outpatient or hospital
visit must be associated with the prescription fill to rea-
sonably conclude that they are related. Most have required
that fills occur within 3 days of a respiratory-related visit.
Exacerbations of asthma and COPD are known to linger
from a few days to several weeks, and in one prospective
clinical study of exacerbations, the median duration was
12 days [60]. It is important to designate the expected
duration of exacerbations so that follow-up visits for one
exacerbation do not get counted as multiple exacerbations.
There are no methods that have near perfect sensitivity or
specificity for capturing COPD or asthma exacerbations,
but the utilization method has demonstrated useful reli-
ability across many patient populations and study designs.
Misclassification errors and extreme outliers can be a
problem in the follow-up period, particularly for persons
labeled with asthma who have vocal cord dysfunction or
conversion disorders, or COPD patients who have hospi-
talizations that last for weeks. Some misdiagnosed asthma
patients can have multiple hospitalizations, including
events that result in intubation and intensive care unit stays.
Pneumonia is often the cause of acute exacerbations of
COPD that result in hospitalization, and hospitalizations
for COPD and pneumonia are substantially longer and
more costly than those without pneumonia [61]. Just a few
outliers or misclassified patients can substantially skew
clinical outcomes, especially costs, and bias CER of ICS/
LABA combinations [58]. Projects using administrative
databases need to be aware of the possibility of extreme
outliers and develop decision rules a priori for exclusion of
extraordinary cases that bias results.
Confounding by events associated with comorbidities is
also a problem in the follow-up period. In a nationwide,
population-based study of comorbidities associated with
COPD, Baty et al. [30] identified a few with the most
prognostic significance among COPD patients who had
hospitalizations related to COPD (N = 160,317 patients).
Lung cancers, lymphatic neoplasms, obesity-hypoventila-
tion syndrome, pseudomonas pneumonia, and secondary
polycythemia were associated with reduced time to
rehospitalization, while asthma was associated with longer
time to rehospitalization. The large number of comorbidi-
ties associated with COPD as compared to age- and sex-
matched controls suggests that a CER project is very likely
to find random differences in comorbidities between trea-
ted COPD groups by chance alone.
6.1 Sensitivity Analyses
Sensitivity analyses are secondary analyses that are inten-
ded to examine assumptions about important covariates,
the impact of specific inclusion/exclusion criteria, and the
differences among various analysis methods. Sensitivity
analyses are especially important in studies that use mul-
tivariable analyses, where the effects of interactions among
covariates can be obscured. Inherent in any study are a
multitude of decisions about classifications and methods.
To the extent possible, decisions that have a greater like-
lihood in impacting findings should be investigated through
sensitivity analyses. For example, decisions about exacer-
bation event duration, assumptions about treatment adher-
ence, or definitions of exacerbations that could vary by the
number of days between a doctor’s visit with a primary
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respiratory diagnosis and an outpatient claim for an OCS,
may need to be tested across a range of alternate values to
see what impact these assumptions may have had on the
final results.
7 Interpretation of Results and Conclusions in CER
An important aspect of CER studies in asthma and COPD
is that they often have multiple outcome measures of
interest (Table 1) which increases the probability that there
will be at least one ‘statistically significant’ difference
between treatments by chance alone (Table 4). Another
aspect to consider is that the database studies often include
thousands of patients, so their size alone gives them power
to detect very small differences between the treatment
groups. However, a small difference between treatment
groups with a p-value well below 0.05, or even 0.001, does
not prove that the difference is either clinically significant
or due to a treatment effect. Absolute standardized differ-
ences can provide better information than p-values about
effect size, and are starting to appear more in published
CER studies. Statistical tests help determine the degree to
which differences can be attributed to random errors, but
study design factors are more important determinants of
establishing causality [62]. One must always keep in mind
that retrospective analyses, because of their high likelihood
of bias, are not reliable proof of causal associations.
However, that is not to say that the results are not valuable.
An analysis that explores the sources of variability and
imprecision among outcomes can reveal very useful
insights into the clinical factors that help determine the
success and failures of treatments in real life.
Determining a clinically important and significant dif-
ference between treatment groups in CER, as opposed to a
statistically significant difference, is a subjective assess-
ment. In most retrospective comparisons from observa-
tional databases, odds ratio differences of less than 2.0
should be regarded with caution [63]. A helpful way to
understand the clinical relevance of a difference in out-
come between two treatments is to present a comprehen-
sive assessment of all demographic and clinical factors
associated with an outcome in the study population, then
compare the magnitude of the treatment-related differences
with the other clinical factors affecting outcome [64]. For
example, a 72 % difference in pneumonia incidence
between two COPD treatment groups with p-value\0.001
may sound like an important finding [22]. However, if the
incidence of pneumonia more than doubles with COPD
severity, various comorbidities, and advanced age, then a
72 % difference could be within the range expected from
selection biases, misclassification errors, and unmeasured
confounders [65].
8 Conclusions
Naturally there is a lot of interest in which treatment is better
when there are choices within the same class. However,
because of the limitations in retrospective study designs and
databases, retrospective analyses of population databases and
observational cohorts can rarely be conclusive about the causal
associations between treatments and outcomes. In our com-
pulsion to see which treatment is better, we often lose sight of
the fact that both treatments are substantially improving out-
comes as compared to those not treated, and the relative dif-
ference between treatments is within the range of random
variation, not only statistically but also in terms of the robust-
ness of the study design. The intense focus on proving which
treatment is ‘better’ can be a distraction away from under-
standing their role and relationships with the other determinates
of overall health outcomes for asthma and COPD patients.
Given the many potential sources of bias that we have
identified in CER studies of asthma and COPD, one might
wonder if these studies are at all reliable or interpretable.
However, if one embraces these sources of variation instead of
hiding or ignoring them, and one directly addresses them in
CER studies, then a truer depiction of how asthma and COPD
patients are managed in real-life can be recognized. Both
reproducibility, referring to method or measurement preci-
sion, and repeatability, referring to agreement across similar
populations, are important concepts for both RCTs and CER
studies. Indeed, much of the value of CER studies lies in the
ability to conduct multiple CER studies using equivalent
methods in an efficient manner using minimal resources.
Additional CER is needed to understand how these treatments
are being used in patients in the general population who do not
fit the restrictive inclusion and exclusion criteria of RCTs.
There is also a need for studies that compare various analysis
approaches and statistical methods to deal with some of the
study design limitations we have discussed, particularly in
treatment adherence and bias by indication.
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